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ABSTRACT
Objectives: This analysis provides an early estimate of the
cost-effectiveness of adjunctive exenatide in treating type 2
diabetes mellitus in the United States. Data from pivotal
phase III 30-week clinical trials and 52 weeks of their subse-
quent open-label extension studies (i.e., 82 weeks total) were
used to project the effects of 30 years of adjunctive exenatide
treatment.
Methods: This analysis utilized a published and validated
Markov model incorporating Monte Carlo simulation with
tracker variables to estimate the clinical and cost outcomes of
adding exenatide to a background of metformin and/or sul-
fonylurea treatment, with the effects of 30 years of adjunctive
exenatide treatment (projected from data from 82 weeks of
exenatide treatment) compared with no additional treatment
beyond metformin and/or a sulfonylurea. Sensitivity analyses
were performed on key clinical assumptions, discount rates,
and shorter time horizons.
Results: The base-case scenario (30 years of exenatide)
yielded an incremental cost-effectiveness ratio (ICER) of
$35,571. We found that shortening the time horizons and
removing the lipid effects of exenatide had the greatest nega-
tive impact on ICERs when performing sensitivity analysis.
Conclusions: Our analysis demonstrated that exenatide used
for 20 or 30 years compared with no additional treatment
beyond metformin and/or a sulfonylurea is cost-effective in
the adjunctive treatment of type 2 diabetes with an ICER less
than $50,000 per life-year gained. Sensitivity analyses suggest
that, in addition to sustained reduction in HbA1c, the added
clinical effects of improved lipid values, systolic blood pres-
sure, and reduced body mass index all positively contributed
to the cost-effectiveness of exenatide.
Keywords: BYETTA, cost-effectiveness, exenatide, modeling,
type 2 diabetes.
Introduction
Type 2 diabetes is a chronic disease characterized by
hyperglycemia caused by progressive failure of the
pancreatic b cells and insulin resistance [1,2]. One of
the earliest manifestations of b-cell dysfunction is a
loss of glucose responsiveness, which occurs many
years before the diagnosis of diabetes. It is estimated
that approximately 50% of b-cell function remains at
the time of diagnosis, with a further loss of approxi-
mately 5% annually thereafter [3]. No existing therapy
has conclusively been shown to halt this progressive
decline in b-cell function. In addition to declining
b-cell function, weight can also contribute to the
pathogenesis of type 2 diabetes, with the risk of devel-
oping type 2 diabetes increasing exponentially with
body-mass index (BMI) [4,5]. In contrast, losing even
modest amounts of weight has been shown to delay the
progression from glucose intolerance to overt diabetes
[6]. For those diagnosed with diabetes, 80% to 90%
are overweight, more than 90% exhibit insulin resis-
tance, and, by deﬁnition, 100% have b-cell dysfunc-
tion [2,5,7]. Given these key associations, weight
control is a cornerstone of diabetes management, and
progressive b-cell dysfunction is a key target for new
therapies.
Current clinical treatment recommendations for
type 2 diabetes generally involve a stepwise approach.
Education centers on exercise and medical nutritional
therapy. If these measures are ineffective, patients are
often started on single oral antidiabetic agents, com-
monly metformin or sulfonylurea [8,9]. These pharma-
cologic therapies are often initially effective, but
frequently become less so over time [9]. Often, addi-
tional oral agents are added, and, when these fail,
increasing doses of exogenous insulin are required in
an attempt to maintain glycemic control [8,9].
Cardiovascular disease accounts for greater than
65% of mortality and morbidity in individuals with
diabetes [10,11]. Accordingly, the clinical focus for
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treating diabetes is to address cardiovascular risk
factors, such as central obesity, hyperglycemia, dyslipi-
demia, and hypertension [12,13]. In addition to the
beneﬁcial effects of managing cardiovascular risk
factors, sustained weight loss and glycemic manage-
ment may lessen the burden of depression, which is
nearly three times as prevalent in people with diabetes
as in the general population [14]. Any weight reduc-
tion may offer other health beneﬁts, because obesity is
associated with many other diseases, including cancer,
osteoarthritis, and gall bladder disease [5,12].
The increasing incidence of diabetes mellitus rep-
resents one of the most serious health challenges
facing the United States. Diabetes and its complica-
tions have been estimated to cost over $130 billion
each year, approximately 10% of total medical care
costs in the United States [15]. Targeting diabetes
care resources to medical interventions that address
the core pathophysiologic defects in a cost-effective
manner is crucial for optimizing the use of health-
care dollars and for managing this epidemic both
now and in the future.
The Academy of Managed Care Pharmacy has rec-
ommended guidelines that call for the economic evalu-
ation of new pharmaceutical compounds to aid
managed care organizations in determining formulary
placement [16]. Although long-term comparative data
with standard of care treatments are the most de-
sirable analyses from a formulary decision-making
standpoint, the available data regarding new pharma-
ceutical compounds are usually limited to placebo-
controlled clinical trials of relatively short duration,
which are then used to support new drug applications.
Economic models can be a useful tool for health-care
decision-makers by utilizing clinical trial data to esti-
mate the long-term clinical and economic impacts of a
speciﬁc medical intervention.
Exenatide (exendin-4) (BYETTA, Amylin Pharma-
ceuticals, Inc., San Diego, CA), which is administered
subcutaneously twice daily b.i.d. before the morning
and evening meals, is the ﬁrst in a class of antidiabetic
therapies called incretin mimetics (approved by the
United States Food and Drug Administration on April
28, 2005). Exenatide is a peptide that exhibits several
of the glucoregulatory properties observed with the
naturally occurring incretin, glucagon-like peptide-1
(GLP-1). Circulating concentrations of GLP-1 are
decreased in people with type 2 diabetes [17]. The
glucoregulatory properties of exenatide are multiple
and result in direct restoration of acute b-cell function
(restoration of ﬁrst-phase insulin secretion and en-
hancement of glucose-dependent insulin secretion) and
a decreased glucose load presented to the failing b cell
(suppression of inappropriately elevated glucagon
secretion, slowing of gastric emptying, and reduction
of food intake). The direct b-cell effects of immediately
restoring ﬁrst-phase insulin secretion and improving
markers of b-cell function (proinsulin:insulin ratio)
over the longer term indicate that this therapy targets
a core defect of diabetes: b-cell dysfunction [17,18]. Of
note, the enhancement of insulin secretion mimics
natural physiology, because it is glucose-dependent.
That is, insulin secretion is only enhanced when
glucose concentrations are elevated. Importantly, in
addition to its b-cell effects, exenatide also causes a
reduction in food intake [19]. These combined effects
position exenatide as the ﬁrst therapy in diabetes to
offer improved glycemic control and signiﬁcant weight
reductions over the longer term.
In three phase III clinical trials of exenatide in
patients with type 2 diabetes who did not achieve
HbA1c less than or equal to 7% with metformin and/or
sulfonylureas, 30 weeks of treatment with 10 mg
exenatide b.i.d. resulted in a mean HbA1c reduction of
approximately 1.0%, along with a mean weight reduc-
tion of approximately 2 kg (Table 1) [18,20,21]. No
signiﬁcant treatment differences were observed for
subgroups categorized by age, sex, or race [22]. The
most frequent adverse event was mild to moderate
nausea, which occurred predominantly at the initiation
of therapy and was ameliorated by initiating therapy
at 5 mg exenatide b.i.d. before titrating to 10 mg
Table 1 Summary of HbA1c and weight changes in the exenatide 30-week pivotal placebo-controlled trials in patients treated on
background therapies of metformin (MET) and/or sulfonylureas (SFU)
Parameter Population N Placebo 5 mg b.i.d. 10 mg b.i.d. Reference
D HbA1c by concomitant treatment MET 336 +0.1% -0.4% -0.8% [18]
SFU 377 +0.1% -0.5% -0.9% [20]
MET + SFU 733 +0.2% -0.6% -0.8% [21]
D HbA1c for baseline HbA1c <9% SFU 239 +0.1% -0.4% -0.7% [20]
MET + SFU 513 +0.3% -0.4% -0.5% [21]
D HbA1c for baseline HbA1c 9% SFU 138 +0.1% -0.6% -1.2% [20]
MET + SFU 220 0.0% -0.9% -1.4% [21]
DWeight by concomitant treatment MET 336 -0.3 kg -1.6 kg -2.8 kg [18]
SFU 377 -0.6 kg -0.9 kg -1.6 kg [20]
MET + SFU 733 -0.9 kg -1.6 kg -1.6 kg [21]
DWeight for baseline BMI <30 kg/m2 MET 89 +0.4 kg -0.5 kg -2.4 kg [18]
DWeight for baseline BMI 30 kg/m2 MET 247 -0.5 kg -2.1 kg -3.0 kg [18]
BMI, body mass index.
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exenatide b.i.d. [18,20,21]. There was also an
increased risk of hypoglycemia when exenatide was
used in conjunction with a sulfonylurea, but not with
metformin. The prescribing information for exenatide
thus recommends that when exenatide is added to a
sulfonylurea, a reduction in the dose of sulfonylurea
may be considered to reduce the risk of hypoglyce-
mia [22]. Another important consideration is that
exenatide is not a substitute for insulin in patients who
require insulin. Furthermore, there is currently no evi-
dence to support the use of exenatide with insulin.
Patients who continued in optional, open-label
extension studies for a total of 82 weeks of exenatide
had a sustained mean HbA1c reduction (-1.1%) and a
progressive mean body weight reduction (-4.4 kg), as
well as signiﬁcant improvements in triglycerides,
high-density lipoprotein cholesterol (HDL-C), and
diastolic blood pressure [23,24]. These results from
82 weeks of exenatide treatment were used in the
present analysis to project the effects of 10, 20, and
30 years of exenatide treatment on background
therapy of metformin and/or sulfonylureas. These
interim data represent the longest exposure to
exenatide treatment to date. Speciﬁcally, we deter-
mined whether adjunctive exenatide treatment would
result in an additional year of life gained for an
expenditure of $50,000 or less. We use this $50,000
ﬁgure for life-year gained (LYG) because that is the
threshold that is generally considered cost-effective
for medical interventions [25].
Methods
Center for Outcomes Research (CORE)
Diabetes Model
The CORE Diabetes Model (CDM) has been described
and validated in two separate publications in a peer-
reviewed journal supplement and is consistent with
recently published American Diabetes Association
modeling guidelines and principles [26–28]. The CDM
is designed to predict the development and progression
of type 1 or type 2 diabetes (through separate and
distinct modules of the model) over long time horizons
(5 years) using the best available published clinical
and epidemiological data. The model has a standard
Markov structure, combined with Monte Carlo simu-
lation and tracker variables, which allows for the
development and progression of multiple complica-
tions within an individual patient, while at the same
time overcoming the memory-free properties of basic
Markov models. For example, traditional Markov
models cannot adjust for changes in risk factors that
affect transition probabilities when a patient with dia-
betes has a myocardial infarction (MI), because the
risk of a future MI event is different if the patient
survives. Once deceased, patients are not included in
the subsequent incidence periods. The transition prob-
abilities for the CDM come from the epidemiological
and clinical studies from the published literature,
including such landmark studies as the United
Kingdom Prospective Diabetes Study (UKPDS) and
Diabetes Control and Complications Trial (DCCT)
studies [29,30]. The process of deciding which transi-
tion probabilities and risk adjustments to incorporate
into the CDM were taken from published resources by
a team of health economists and clinicians, as fully
described in Palmer et al. 2004 [27].
The CDM design includes 15 submodels that simu-
late diabetes-related complications (angina, cataract,
congestive heart failure, foot ulcer and amputation,
hypoglycemia, ketoacidosis, lactic acidosis, macular
edema, myocardial infarct (MI), nephropathy, neur-
opathy, peripheral vascular disease, retinopathy, and
stroke) and nonspeciﬁc mortality [27]. During a simu-
lation, all submodels run in parallel to allow patients
to develop complications concomitantly (where appro-
priate and documented in peer-reviewed clinical and
epidemiological literature). Where published data indi-
cate that the presence of one complication increased
the probability of another complication occurring, that
increased probability for the second complication
was incorporated into the model as time progresses
through the simulation exercise.
CDM Substantiation
The CDM was validated through 66 separate analy-
ses, which covered the published epidemiological and
clinical studies used to create the model (second-
order), along with published epidemiological and
clinical studies not used to create the model (third-
order) [28]. The published clinical and epidemiologi-
cal studies used to validate the model were selected
based on the availability of appropriate outcome
data, the quality of the study design, and the avail-
ability of appropriate baseline population risk
factors, including HbA1c, systolic blood pressure,
total cholesterol, HDL-C, low-density lipoprotein
cholesterol (LDL-C), triglycerides, and BMI [28]. Sec-
ondly, studies were chosen that described a range of
type 2 diabetic populations, treatments, product
delivery settings, and resulting outcomes [28]. Lastly,
published studies were chosen based on the breadth
of coverage for speciﬁc diabetic complications (e.g.,
Wisconsin Epidemiological Study of Diabetic Retin-
opathy for retinopathy outcomes) and time periods
(from 1960 to 2003) [28].
Exenatide
This economic-modeling study uses data from those
314 patients who completed 82 weeks of treatment
with exenatide to project the effects of 30 years of
exenatide treatment. The primary objective of the
extension phase of the trials was to examine the long-
term effects of exenatide (10 mg b.i.d.) on glycemic
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control (HbA1c), safety, and tolerability. Safety end
points included adverse events occurring upon or after
receiving the ﬁrst exenatide dose during the placebo-
controlled trials through the 82-week period, as well as
clinical laboratory tests, physical examination, 12-lead
ECG, and vital signs. Change in body weight and
fasting lipids were secondary end points.
Simulation Cohort
The theoretical population of 1000 patients used in
this exercise 1000 times was based on patients with
type 2 diabetes who did not achieve adequate glycemic
control with metformin and/or sulfonylureas and who
were subsequently treated with exenatide in addition
to their pre-existing oral antidiabetic regimen. Speciﬁc
demographic characteristics, such as age, sex, race,
duration of diabetes, baseline HbA1c, and baseline BMI
were taken from the same group of patients with type
2 diabetes who completed 82 weeks of treatment in
the exenatide open-label extension studies (N = 314)
(Table 2). Other characteristics taken from this group
of patients included baseline values for cardiovascular
risk factors, such as systolic blood pressure, total cho-
lesterol, HDL-C, LDL-C, and triglycerides. There
were, however, some characteristics, such as baseline
prevalence of diabetes-related diseases and proportion
of patients receiving speciﬁc treatments relevant to
diabetes, which were not available for this exenatide-
treated population. Therefore, we used published data
for general type 2 diabetes populations for the fol-
lowing characteristics: prevalence of cardiovascular
disease, renal disease and retinopathy; proportion of
patients treated with angiotension converting enzyme
inhibitors, statins, and aspirin; and proportion of
patients screened for retinopathy, renal disease, and
foot disease.
Treatment Effects
The clinical effects of exenatide over 82 weeks, includ-
ing changes in HbA1c, lipid parameters, BMI, and sys-
tolic blood pressure used in the modeling to project the
effects of 30 years of exenatide treatment, are detailed
in Table 3. Exenatide showed consistent and sustained
reductions over the 82-week treatment period inHbA1c,
BMI, and triglycerides, coupled with an increase in
HDL-C [23,24]. After the initial 82-week exenatide
extension phase study data set, long-term changes in
HbA1c were assumed to follow the UKPDS trend, which
demonstrated an annual increase of 0.15%/year [30].
This approach likely underestimates the cost-
effectiveness of exenatide, because further clinical data
suggest that the reduction in HbA1c observed with
exenatide over 82 weeks is sustained for at least 2 years
[31]. Other parameters, such as systolic blood pressure,
BMI and cholesterol, were assumed to not change after
week 82. Again, this 82-week data was used to project
the effects of 30 years of exenatide treatment. Because
the exenatide open-label extension study did not
contain a placebo arm, we compared exenatide with a
group that received no additional treatment beyond
metformin and/or a sulfonylurea and that assumed
continued disease progression with no cost and no
clinical effect of therapy.
Table 2 Characteristics of a type 2 diabetes population used in
constructing the simulation cohort (based on the 82-week
exenatide cohort and published descriptions of type 2 diabetes
populations) (N = 314)
Characteristic
Baseline
value SD Reference
Patient demographics
Mean age (years) 56 10 [23]
Duration of diabetes (years) 7 6 [23]
Proportion male 63% [23]
Risk factors
HbA1c (%) 8.3 1.0 [23]
Systolic blood pressure (mm Hg) 128.6 13.7 [23]
Body mass index (kg/m2) 34 6 [23]
Total cholesterol (mg/dL) 185.9 39.3 [23]
High-density lipoprotein cholesterol
(mg/dL)
38 9.1 [23]
Low-density lipoprotein cholesterol
(mg/dL)
115.1 35.7 [23]
Triglycerides (mg/dL) 239 181.6 [23]
Ethnic group (%)
White 78 [23]
African American 11 [23]
Hispanic 9 [23]
Asian 1 [23]
Other 1 [23]
Cardiovascular disease (%)
Stroke 8.4 [41]
Angina pectoris 11.2 [41]
Myocardial infarction 15.0 [41]
Congestive heart failure 11.8 [42]
Atrial ﬁbrillation 0.75 [43]
Left ventricular hypertrophy
detected by ECG
4.2 [44]
Peripheral vascular disease 14 [45]
Renal disease (%)
Microalbuminuria 28.2 [46]
Gross proteinuria 7.6 [46]
End-stage renal disease 0.4 [46]
Retinopathy (%)
Background diabetic retinopathy 39.0 [41]
Proliferative diabetic retinopathy 3.0 [41]
Other complications (%)
Peripheral neuropathy 40.0 [47]
Foot ulcer 10.5 [48]
Amputation 2.6 [48]
Cataract 14.0 [41]
Macular edema 4.0 [41]
Severe vision loss 2.2 [41]
Patient management of type 2
diabetes (%)
Taking angiotensin-converting
enzyme-inhibitor (ACE-I)/
angiotension receptor blocker
(ARB)
50.0 [49]
Taking statins 45.0 [50]
Taking aspirin 45.6 [51]
Screened for retinopathy (assumed
to be treated with laser if
detected)
74.0 [45]
Screened for renal disease (assumed
to be treated with ACE-I or ARB
if detected)
55.0 [45]
Screened for foot disease 87.0 [45]
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Costs and Perspective
A third-party (Medicare) payer perspective was used
for this analysis. Descriptions of the event, state, and
other direct medical costs used in this modeling exer-
cise were based on data previously published by
Palmer et al. [27]. The costs for treating diabetes-
related complications were inﬂated to 2005 $US using
the consumer price index for the health-care sector
[32] and were taken from published resources
(Table 4). The cost of exenatide ($US5.75 per day of
therapy, annual cost of $2099 assuming 365 days of
therapy) was the initial published wholesale average
cost price from May 2005, while the cost for no addi-
tional treatment beyond metformin and/or a sulfony-
lurea was assumed to be zero.
Type 2 Utility Values
Cost-effectiveness was also determined for quality-
adjusted life-year (QALY) gained. Utility values to
calculate QALY were based on data from patients
with type 2 diabetes in the Cost of Diabetes in
Europe—Type II diabetes (CODE-2) study, one of the
few studies in type 2 diabetes assessing utility values.
Speciﬁcally, while the entire study evaluated more than
7000 patients with type 2 diabetes in eight European
countries, a subset of these patients, 4641 from ﬁve
Table 3 Treatment effects for exenatide: 82-week data summary (used to project effects of 30 years of exenatide treatment)
Intermediate clinical outcome Change in baseline value SD Reference
HbA1c (%) -1.1 1.3 [24]
Systolic blood pressure (mm Hg) -1.3 16.4 [24]
Body mass index (kg/m2) -1.5 2.0 Data on File,Amylin
Pharmaceuticals, Inc.
Total cholesterol (mg/dL) -2.4 35.1 [24]
High-density lipoprotein cholesterol (mg/dL) 4.6 7.8 [24]
Low-density lipoprotein cholesterol (mg/dL) -1.6 31.9 [24]
Triglycerides (mg/dL) -39 153 [24]
Table 4 Event, state, and other costs used in the Center for Outcomes Research Diabetes Model expressed in $US, inﬂated to 2005
values for the United States
Description of event or state Cost per event or state ($) Reference
Myocardial infarction, year of event 35,065 [52]
Myocardial infarction, each subsequent year 1,938 [52]
Angina, year of onset 6,956 [52]
Angina, each subsequent year 1,797 [52]
Congestive heart failure, year of onset 3,012 [52]
Congestive heart failure, each subsequent year 3,012 [52]
Stroke, year of event 46,434 [52]
Stroke, each subsequent year 15,497 [52]
Peripheral vascular disease, onset 4,410 [53]
End-stage renal disease 42,763 [52]
Retinal photocoagulation 781 [52]
Severe vision loss/blindness, year of onset 3,784 [52]
Severe vision loss/blindness, subsequent years 3,784 [52]
Cataract extraction 2,488 [53]
Neuropathy, onset 382 [52]
Uninfected ulcer 1,658 [54]
Infected ulcer 2,997 [54]
Gangrene 5,847 [54]
Amputation, year of event 31,162 [52]
Amputation, years 2+ after event 1,120 [52]
Ketoacidosis event 12,560 [52]
Major hypoglycemic event 257 [52]
Annual cost aspirin 22 [55]
Annual cost statins (assume simvastatin 10 mg @$238/100 tablets, inﬂated to $US 2005) 888 [55]
Annual costs angiotensin converting enzyme inhibitor (based on 25 mg Captopril Tris In Diem) 399 [56]
Annual costs for exenatide ($5.75/day of therapy, published wholesale average cost price for Exenatide,
published in May, 2005)
2,099 —
No additional treatment comparator cost 0 —
Costs of screening for retinopathy 77 [52]
Costs of screening for microalbuminuria 17 [52]
Costs of screening for gross proteinuria 26 [52]
Costs (monthly) nonstandard ulcer treatment (Regranex) 157 [57]
Capoten (captopril), Bristol Myers Squibb, Princeton,NJ; Regranex gel (beclaplermin),Ortho-McNeil Pharmaceutical, Raritan,NJ; Zocor (simvastatin), Merck and Co.,Whitehouse
Station, NJ.
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countries, responded to the EuroQol EQ-5D question-
naire [33,34]. The questionnaire responses provided a
large set of relevant patient data, which were then used
to model health-related utility values from both visual
analog scale and time trade-off index scores. The
CODE-2 analyses reported in this article used said
utility values. Of note, these utility values do not
account for effects related to weight reductions, and so
may not capture the full effects of exenatide on quality
of life.
Time Horizon and Discounting
The simulation was run over a 30-year period, consis-
tent with current guidelines, which recommend that
the time horizon be sufﬁcient to capture the develop-
ment of long-range disease complications [35]. Costs
and clinical outcomes were both discounted at 3% per
annum, also in accordance with published US recom-
mendations [35]. This discounting adjusts for esti-
mated inﬂation of health-care costs.
Sensitivity Analyses
Exploratory simulations were run on shorter time
horizons of 10 and 20 years. Annual discount rates of
0% and 6% were also examined. Additional sensitivity
analyses were performed on the following clinical
parameters: varying the observed HbA1c change
(20%), removing the BMI effects, removing the lipid
effects, and removing the blood pressure effects.
Analyses were also performed with the HbA1c changes
observed for those patients with baseline HbA1c less
than 9% as compared with patients with baseline
HbA1c greater than or equal to 9%. Lastly, the analysis
was performed using the week 30 data for the 82-week
cohort.
Probabilistic Sensitivity Analysis
The range of clinical values used in the probabilistic
sensitivity analysis was derived from the 82-week
exenatide data for the base-case analysis (Table 3). We
evaluated the individual contributions of each clinical
element of exenatide treatment by removing each of
the effects individually, then comparing the resulting
incremental cost-effectiveness ratio (ICER) with the
base-case ICER. This provides an indication of the
relative contribution of each clinical variable to
the overall ICER. For example, we removed the BMI
effect (i.e., reductions in body weight) and calculated
the ICER without this clinical effect. We then com-
pared this ICER with the base-case ICER. We did the
same for changes in lipids (total cholesterol, HDL-C,
LDL-C, and triglycerides), as well as for systolic blood
pressure, to examine the role of each of these variables
in the overall ICER value. In essence, the probabilistic
sensitivity analysis was used to value each part of the
exenatide proﬁle individually to allow payers to evalu-
ate the relative contribution of each clinical element to
the entire product proﬁle.
Bootstrapping
A nonparametric bootstrapping technique was used to
explore uncertainty in clinical and cost outcomes for
the CDM simulations [36]. In summary, each transi-
tion probability used in the CDM was simulated by
applying ﬁrst-order Monte Carlo simulation tech-
niques to characterize sampling uncertainty [27]. The
bootstrap analysis was then performed by simulating
costs and outcomes for 1000 theoretical patients, with
each patient proceeding through the model 1000
times. The mean costs and outcomes were then calcu-
lated from these simulations. This simulation was per-
formed for the base case and repeated for all sensitivity
analyses.
Results
Base-Case Analysis
The 30-year base-case analysis showed that 30 years of
adjunctive exenatide treatment (based on the projected
effects from data from 82 weeks of exenatide treat-
ment) in patients with type 2 diabetes not achieving
adequate glycemic control with metformin and/or
sulfonylureas, compared with a hypothetical no
additional treatment arm (i.e., nothing in addition
to metformin and/or a sulfonylurea), demonstrated
improved clinical outcomes at a higher cost per patient
(Table 5). Exenatide demonstrated a mean discounted
life expectancy of 9.63 years and mean total costs of
$86,281 per patient, compared with 9.10 years and
mean total costs of $67,531 per patient if no addi-
tional treatment were added. The resulting ICER for
30 years of exenatide treatment was $35,571/LYG
(Table 6). When this analysis was repeated for QALY
using CODE-2 utility values, the mean discounted life
Table 5 Summary results for the base-case analysis
30-year time horizon Exenatide
No additional treatment
beyond MET and/or SFU
Total costs as mean (SD) per patient, discounted at 3% annually ($US) 86,281 (2,401) 67,531 (2,438)
Life expectancy mean (SD) (years) 9.63 (0.18) 9.10 (0.17)
Quality-adjusted life expectancy (34) (years) 6.33 (0.12) 5.81 (0.11)
MET, metformin; SFU, sulfonylurea.
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expectancy for exenatide was 6.33 QALY, compared
with 5.81 QALY for no additional treatment. The
resulting CODE-2 ICER for 30 years of exenatide
treatment was $36,133/QALY (Table 6). A shorter
time horizon of 10 years demonstrated a larger ICER
and CODE-2 ICER of $100,633/LYG and $64,538/
QALY, respectively, while a 20-year horizon resulted in
an intermediate ICER and CODE-2 ICER of $42,732/
LYG and $39,219/QALY, respectively.
The cumulative incidence of diabetes complications
is described for the 10-, 20-, and 30-year time horizons
for both groups to demonstrate which diabetes com-
plications account for greater differences in clinical
outcomes over the three simulation periods (Table 7).
These data suggest that 30 years of adjunctive
exenatide treatment, in addition to metformin and/or
sulfonylurea treatment, compared with no additional
therapy, may have a meaningful impact on reducing
the incidence of MI, eye disease, renal disease, and
neuropathy complications over time.
The incremental cost-effectiveness scatter plot
displays the difference in mean costs plotted against
the difference in mean life expectancy between the
exenatide and comparison group for 1000 patients
both for the base-case situation (Fig. 1A) and for
QALY (Fig. 1B). The majority of points in both scatter
plots are in the upper right quadrant, indicating that
exenatide was both more costly and more effective
than adding no additional therapy. When the scatter
plots were converted into a cost-effectiveness probabil-
ity curve (Fig. 2), the probability that the treatment
cost to obtain an additional year of life with exenatide
would be $50,000 or less was 74% for the base case
and 81% for QALY. These were in comparison with
the theoretical no additional treatment option.
Sensitivity Analysis
Reducing the HbA1c effectiveness of exenatide by a
theoretical 20% (i.e., from -1.1% to -0.88%) likewise
increased the ICER from $35,571/LYG in the base case
to $ 42,875/LYG, and the CODE-2 ICER from
$36,133/QALY to $41,917/QALY. Assuming no
impact of exenatide on BMI (changing from
-1.5 kg/m2 in the base case to 0 kg/m2) or systolic
Table 6 Summary results at 10-, 20- and 30-year time horizons (exenatide compared with no additional treatment)
Time
horizon
D Life
expectancy (years)
D Quality-
adjusted life
expectancy (years)
D Costs
($)
ICER (life
expectancy)
($/year or QALY)
ICER (quality-
adjusted life expectancy)
($/year or QALY)
10-year 0.124 0.193 12,429 100,633 64,538
20-year 0.394 0.429 16,843 42,732 39,219
30-year 0.527 0.519 18,750 35,571 36,133
ICER, incremental cost-effectiveness ratio.
Table 7 Cumulative incidence of complications over time in the theoretical cohort of 1000 patients with type 2 diabetes over 10-,
20- and 30-year time horizons (in addition to baseline prevalence)
System Complication
Incidence SD (%)
10 years 20 years 30 years
Exenatide
No additional
treatment Exenatide
No additional
treatment Exenatide
No additional
treatment
Vision Background diabetic retinopathy 8.79 1.22 13.61 1.42 17.20 1.67 23.02 1.74 20.63 1.66 25.57 1.76
Proliferative diabetic retinopathy 0.81 0.30 1.34 0.34 1.77 0.44 2.65 0.52 2.39 0.50 3.32 0.56
Cataract 4.49 0.67 5.38 0.76 7.25 0.84 8.22 0.93 8.09 0.96 8.95 1.01
Macular edema 6.62 0.79 10.40 0.99 13.40 1.18 18.40 1.25 16.45 1.17 20.94 1.41
Severe vision loss 3.69 0.63 4.73 0.67 7.60 0.89 9.52 0.97 9.58 0.97 11.19 0.98
Renal Microalbuminuria 13.24 1.33 19.62 1.53 24.22 1.69 31.01 1.90 28.49 1.79 34.56 1.82
Gross proteinuria 3.97 0.64 6.83 0.83 10.13 0.97 15.14 1.20 14.03 1.18 18.62 1.28
End-stage renal disease 0.89 0.29 1.67 0.43 2.80 0.51 4.99 0.72 4.96 0.71 7.39 0.81
Nephropathy death 0.62 0.25 1.00 0.32 1.80 0.42 3.16 0.57 3.33 0.59 5.05 0.71
Cardiovascular Myocardial infarction 8.62 0.85 12.13 1.03 17.58 1.23 23.08 1.33 21.92 1.31 27.11 1.44
Myocardial infarction death 12.12 1.04 14.04 1.12 20.63 1.33 23.85 1.37 24.29 1.40 27.40 1.41
Stroke event 3.97 0.60 4.13 0.65 8.43 0.88 8.24 0.87 11.42 0.99 10.58 0.95
Stroke death 2.90 0.52 2.84 0.51 5.11 0.72 4.96 0.66 6.41 0.76 5.98 0.75
Congestive heart failure 15.73 1.23 18.95 1.33 29.78 1.50 34.19 1.63 36.41 1.55 39.33 1.57
Congestive heart failure death 7.85 0.87 8.57 0.91 16.69 1.19 18.05 1.23 22.15 1.26 22.45 1.24
Peripheral vascular disease 4.00 0.65 6.29 0.83 10.31 1.01 14.68 1.18 14.71 1.23 18.69 1.33
Angina 6.20 0.83 7.67 0.88 10.93 1.06 12.97 1.17 12.99 1.09 14.68 1.23
Extremities Peripheral neuropathy 25.52 1.81 34.64 1.93 42.17 2.05 50.80 2.22 46.17 2.09 52.48 2.08
Foot ulcer 14.60 1.11 15.36 1.12 23.10 1.32 24.32 1.39 26.39 1.44 26.93 1.45
Recurring foot ulcer 20.56 1.96 20.45 1.99 35.78 2.99 35.56 3.01 41.69 3.33 40.58 3.32
Amputation from foot ulcer 5.23 0.79 5.36 0.76 8.47 1.03 8.60 1.05 9.67 1.02 9.4 1.05
Amputation from recurring foot ulcer 1.69 0.49 1.64 0.45 3.19 0.72 3.12 0.66 3.83 0.75 3.57 0.75
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Figure 1 Scatter plots of 1,000 samples of mean incremental costs plotted against mean incremental life-expectancy (life-years gained or quality-adjusted
life-years gained).The scatter plots were generated for the mean incremental costs of 1,000 patients comparing exenatide with a theoretical no additional
treatment option (metformin and/or a sulfonylurea only) for incremental life expectancy under the base-case scenario for life-year gained (A) or
quality-adjusted life-year gained (B). For both plots, the majority of the points lie in the upper right-hand quadrant, indicating higher costs and improved
effectiveness for exenatide compared with a theoretical no additional treatment option.
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blood pressure (from -1.3 mm Hg to 0 mm Hg) had
little impact on the ICERs. Lastly, removal of the lipid
effects (total cholesterol from -2.4 mg/dL to 0 mg/dL;
LDL-C from -1.6 mg/dL to 0 mg/dL; HDL-C from
4.6 mg/dL to 0 mg/dL; and triglycerides from
-39 mg/dL to 0 mg/dL) had the largest impact on the
base-case ICER, increasing it by approximately 26%
to $44,950/LYG. The CODE-2 ICER increased to a
lesser degree, by 16% to $41,738/QALY. Decreasing
the discount rate from 3% to 0% decreased the ICER
approximately 17% to $29,397/LYG, and CODE-2
ICER by 7% to $33,751/QALY. Increasing the dis-
count rate from 3% to 6% increased the ICER
approximately 22% to $43,267/LYG, and CODE-2
ICER by 5% to $38,114/QALY.
Patients with baseline HbA1c less than 9% had
HbA1c changes of -0.8%, as compared with -2.0% for
those with baseline HbA1c greater than or equal to 9%.
The corresponding ICERs for the two baseline HbA1c
subgroups were $48,284/LYG and $18,243/LYG,
respectively. The CODE-2 ICERs for these two sub-
groups were $45,971/QALY and $20,548/QALY.
Analysis of week 30 data (from the 82-week cohort)
resulted in an ICER of $51,354/LYG, while the
CODE-2 ICER was $47,981/QALY.
Discussion
Our early modeling study suggests that sustained
glycemic control and progressive weight reduction
leading to positive clinical effects on lipids, BMI, and
systolic blood pressure all contribute to the projected
long-term cost-effectiveness of adjunctive exenatide
treatment for patients with type 2 diabetes not achiev-
ing adequate glycemic control with metformin and/or
a sulfonylurea, as compared with adding no additional
therapy to metformin and/or a sulfonylurea when mea-
sured for either a 20-year or a 30-year time horizon.
Use of a 10-year time horizon with diabetes is some-
what difﬁcult to interpret, because many of the com-
plications associated with diabetes develop over the
course of decades, not years. Therefore, it would
be unlikely that any diabetes treatment would show
cost-effectiveness for this time horizon. The cost-
effectiveness of exenatide is in large part due to ben-
eﬁcial effects on lipids, which thus reduce the risk of
cardiovascular disease. Not surprisingly, given this
projected relationship with cardiovascular disease,
exenatide treatment was not cost-effective when exam-
ined for a 10-year time horizon. As the incidence of
complications rise with longer time horizons, the ben-
eﬁts of exenatide in reducing their incidence become
more evident. The difference in results with the differ-
ent time horizons highlights the beneﬁt of using longer-
term time horizons, which capture these chronic
conditions. These longer time horizons are consistent
with various guidelines that maintain that any eco-
nomic modeling analysis in diabetes must be carried on
long enough to capture all of the relevant outcomes of
interest [35,37].
The positive clinical effects of exenatide could
translate into reduced incidence of long-term diabetic
complications, reduce long-term treatment costs, and
improve life expectancy for patients with type 2 dia-
betes in the United States. The conclusions of this early
modeling study suggest that the study results were also
robust over a wide range of clinical and economic
assumptions, including discount rates and clinical
effects. The ICERs for the base case and most sensitiv-
ity analyses fell below $50,000/LYG or QALY, a
threshold that is considered cost-effective in the United
States [25,38].
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Figure 2 Probability of life-year gained or
quality-adjusted life-year gained with exenatide
plotted against expenditure. The curves were
generated for probability life-year gained or
quality-adjusted life-year gained compared with
expenditure from 1,000 samples for 1,000
patients treated with exenatide compared with
a theoretical no additional treatment option
(metformin and/or sulfonylurea only).The curve
shows how likely (y-axis) it will be that
exenatide is cost-effective for any particular
expenditure (x-axis). The probability that the
treatment cost to obtain an additional year of
life with exenatide would be $50,000 or less
was 74% for life-year gained and 81% for quality-
adjusted life-year gained, as compared with a
theoretical no additional treatment option.
30 Minshall et al.
The chief limitation of our economic analysis of
exenatide is the lack of clinical data directly compar-
ing exenatide with other type 2 diabetes treatments.
Although some of these studies are underway, the
current paucity of data and the lack of a true placebo
comparator arm (beyond the initial 30 weeks of
treatment) required us to pursue a preliminary com-
parison of exenatide with a theoretical no additional
treatment beyond metformin and/or a sulfonylurea
option, with no added costs and no clinical effects.
This is clearly a drawback of our analysis. Neverthe-
less, this lack of long-term or comparative data is
common when a new product is introduced, because
most registration trials are placebo-controlled for a
relatively short duration. With this in mind, we pro-
vided a preliminary analysis on the cost-effectiveness
of exenatide with the full realization that our clinical
and comparative data are limited. We used the
exenatide 82-week data to project the effects of
30 years of exenatide treatment, because these data
represent the longest-term and most robust source of
data at this time. Longer-term data (2 years from the
same study and 2.5 years from an open-label study)
demonstrate that with continued exenatide treatment
glycemic control is sustained and weight reduction is
progressive, with further beneﬁcial changes in lipid
concentrations [31,39]. These data indicate that, if
anything, the current analysis underestimates the
cost-effectiveness of exenatide.
Other limitations of our analysis include the
assumption that the difference in HbA1c between
exenatide and the theoretical no additional treatment
arm would be maintained over the entire analysis
time horizon. This assumption is common practice in
health economic modeling analyses in diabetes, espe-
cially when clinical experience with a new treatment
is limited. Nonmedical costs, such as lost productivity
and transportation costs, are excluded and could lead
to an underestimation of costs from a broader per-
spective. Also, this model utilizes data from credible
sources to calculate epidemiological risk functions.
As such, this may diminish the potential contribution
of risk factors for which available data are currently
sparse. Postprandial control, for example, is increas-
ingly being recognized as a potentially important risk
factor that independently contributes to the develop-
ment of macrovascular complications [40]. The
model does not factor in the potential impact of post-
prandial glycemia effects because the current evidence
base is not sufﬁcient to inform the model with any
degree of scientiﬁc certainty. Of note, exenatide has
been shown to signiﬁcantly reduce postprandial
glucose excursions. In addition, the clinical beneﬁt of
reduced BMI, independent of the known effects on
improved cardiovascular disease markers, is not fully
known. As more clinical research is performed in the
area of weight reduction, it may become apparent
that this model does not fully capture the range of
clinical beneﬁts associated with weight reduction. On
a related note, the CODE-2 study, which formed the
basis for the utility values used in the quality of life
analysis, did not account for utility associated with
weight reduction. Additional studies in patients with
type 2 diabetes are needed to determine to what
extent weight reductions impact quality of life, and
thus cost-effectiveness.
Further research should focus on increasing the
amount of long-term clinical data with exenatide,
including comparative data with other clinical treat-
ments for type 2 diabetes, and on accounting for other
positive clinical effects of exenatide, such as postpran-
dial glucose control and weight reduction.
Conclusions
Our analysis demonstrated that using 30-year base-
case assumptions and data from 82 weeks to project
the effects of 30 years of exenatide treatment,
exenatide provides good value for money in the treat-
ment of patients with type 2 diabetes not achieving
adequate glycemic control with metformin and/or
sulfonylureas, with an ICER of $35,571/LYG and
$36,133/QALY, compared with no additional treat-
ment beyond metformin and/or a sulfonylurea. When
assumptions were varied (for HbA1c, BMI, lipid, and
blood pressure effects), the ICERs remained less than
$50,000/LYG in most sensitivity analyses. Speciﬁcally,
the largest effects were observed when varying the time
horizon, HbA1c effect, and lipid changes (in that
order). Varying the BMI and blood pressure effects,
however, did not signiﬁcantly affect the cost-
effectiveness.
This early economic modeling analysis can provide
managed care formularies and other health-care payers
with important information on the economic value of
another option to treat type 2 diabetes in the United
States. Our analysis is the ﬁrst step in documenting the
cost-effectiveness of exenatide in type 2 diabetes and
informing future health-care decision-making in the
United States.
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